William Blair Brokers Lower Earnings Estimates for Natus Medical Inc. (BABY)
Natus Medical Inc. (NASDAQ:BABY) – William Blair decreased their FY2016 earnings per share estimates for shares of Natus Medical in a report released on Tuesday. William Blair analyst B. Weinstein now expects that the brokerage will post earnings per share of $1.62 for the year, down from their previous estimate of $1.73. William Blair also issued estimates for Natus Medical’s FY2017 earnings at $1.75 EPS.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.03. The business earned $96 million during the quarter, compared to the consensus estimate of $92.71 million. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.34 earnings per share.
Several other research firms have also weighed in on BABY. Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Thursday, July 7th. Raymond James Financial Inc. raised shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price objective for the company in a report on Tuesday, September 13th.
Shares of Natus Medical (NASDAQ:BABY) opened at 39.04 on Thursday. The firm has a 50-day moving average price of $40.39 and a 200-day moving average price of $36.82. Natus Medical has a 52-week low of $29.54 and a 52-week high of $51.05. The firm has a market capitalization of $1.27 billion, a P/E ratio of 33.66 and a beta of 0.85.
Hedge funds have recently modified their holdings of the stock. BlackRock Group LTD raised its stake in shares of Natus Medical by 5.9% in the first quarter. BlackRock Group LTD now owns 50,792 shares of the company’s stock worth $1,952,000 after buying an additional 2,839 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Natus Medical by 227.5% in the first quarter. JPMorgan Chase & Co. now owns 96,350 shares of the company’s stock worth $3,703,000 after buying an additional 66,933 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Natus Medical by 13.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 953,413 shares of the company’s stock worth $36,640,000 after buying an additional 112,582 shares in the last quarter. Invictus RG bought a new stake in shares of Natus Medical during the first quarter worth $148,000. Finally, Geneva Advisors LLC raised its stake in shares of Natus Medical by 104.5% in the second quarter. Geneva Advisors LLC now owns 27,963 shares of the company’s stock worth $1,057,000 after buying an additional 14,287 shares in the last quarter. 87.92% of the stock is owned by institutional investors and hedge funds.
In related news, insider James B. Hawkins purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, September 28th. The stock was acquired at an average price of $38.48 per share, with a total value of $384,800.00. Following the completion of the acquisition, the insider now directly owns 459,725 shares in the company, valued at approximately $17,690,218. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.80% of the stock is currently owned by corporate insiders.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related stocks with our FREE daily email newsletter.